JS 001

Drug Profile

JS 001

Alternative Names: Anti-PD1 monoclonal antibody - Shanghai Junshi

Latest Information Update: 10 Jan 2017

Price : $50

At a glance

  • Originator Shanghai Junshi Biosciences
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Immunomodulators; PDCD 1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Malignant melanoma
  • Phase I Breast cancer; Lymphoma; Solid tumours; Urogenital cancer

Most Recent Events

  • 01 Dec 2016 Phase-II clinical trials in Malignant melanoma (Late-stage disease, Second-line therapy or greater, Metastatic disease, Monotherapy) in China (IV) (NCT03013101)
  • 23 Sep 2016 Shanghai Junshi Bioscience plans a phase Ib/II trial for Gastric cancer, Nasopharyngeal cancer, Oesophageal cancer and Head and neck cancer (Late-stage disease, Recurrent, Metastatic disease, Second-line therapy or greater) in China (IV) (NCT02915432)
  • 01 Aug 2016 Phase-I clinical trials in Lymphoma (Late-stage disease, Recurrent, Second-line therapy or greater) in China (IV) (NCT02836834)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top